Hematopoietic Stem Cell Transplantation (HSCT) is a potentially curative but risky therapy for hematological malignancies.
Our group is focused on harnessing advanced prognostic tools, including Machine Learning (ML), for prediction of HSCT outcomes and treatment personalization.
Our previous experience includes development and validation of an ML based prediction model for short term mortality (TRM) post allogeneic HSCT in acute leukemia, analysis of TRM prediction limiting factors using an in-silico approach, and development of a risk score for survival following umbilical cord blood transplantation in acute leukemia.
This work is conducted in collaboration with the following: The Hematology and Bone Marrow Transplantation Division, Talpiot Medical Leadership Program, The Chaim Sheba Medical Center, Tel-HaShomer.
Our group is focused on harnessing advanced prognostic tools, including Machine Learning (ML), for prediction of HSCT outcomes and treatment personalization.
Our previous experience includes development and validation of an ML based prediction model for short term mortality (TRM) post allogeneic HSCT in acute leukemia, analysis of TRM prediction limiting factors using an in-silico approach, and development of a risk score for survival following umbilical cord blood transplantation in acute leukemia.
This work is conducted in collaboration with the following: The Hematology and Bone Marrow Transplantation Division, Talpiot Medical Leadership Program, The Chaim Sheba Medical Center, Tel-HaShomer.
Contact info:
Dr. Roni Shouval MD
Sheba Medical Center
